Literature DB >> 7535016

Surgical treatment of carcinoma of the proximal esophagus.

J P Marmuse1, V N Koka, C Guedon, G Benhamou.   

Abstract

BACKGROUND: Proximal esophageal cancer is usually diagnosed at an advanced stage, and the treatment is often limited to palliation. Surgery offers the best relief of dysphagia but it remains controversial, because a cure is unlikely even at the price of laryngeal mutilation. PATIENTS AND METHODS: We treated 40 patients with transhiatal esophagectomy for cancer of the proximal esophagus. The esophageal substitute was a stomach tube in 37 patients and colon in 3 patients. The larynx was preserved in 27 patients whose tumors did not extend to cricopharyngeus. Adjuvant treatment consisted of postoperative radiotherapy for 22 patients, chemotherapy for 1 patient, and a multimodality regimen for 4 patients.
RESULTS: The postoperative complication and hospital mortality rates with gastric tube transpositions were 22% and 8%, respectively, with a 3% fistula rate. The 1- and 3-year overall survival rate was 53% and 21%, respectively. The unfavorable prognostic factors were tumor wall penetration, lymph nodal involvement, and cricopharyngeal involvement. Local recurrence of cancer was the major cause of failure.
CONCLUSIONS: These results indicate that transhiatal esophagectomy with gastric tube transposition offers good palliation of dysphagia with low morbidity and mortality for proximal esophageal cancer. The laryngeal preservation can be attempted for tumors located close to, but not involving, the cricopharyngeus in order to retain speech in patients with a limited life expectancy.

Entities:  

Mesh:

Year:  1995        PMID: 7535016     DOI: 10.1016/s0002-9610(99)80182-2

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  [The carotid artery as recipient vessel: troubleshooting for free jejunal transfer after esophagectomy in preradiated patients].

Authors:  D F Müller; J A Lohmeyer; A Zimmermann; J R Siewert; L Kovacs; H-G Machens; E Biemer
Journal:  Chirurg       Date:  2011-08       Impact factor: 0.955

2.  Characteristics of esophagorespiratory fistulas resulting from esophageal cancers: a single-center study on 243 cases in a 20-year period.

Authors:  Akos Balazs; Zoltan Galambos; Peter K Kupcsulik
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

Review 3.  Treatments for esophageal cancer: a review.

Authors:  Hiroyuki Kato; Masanobu Nakajima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-04-09

4.  Influence of resection extent on morbidity in surgery for squamous cell cancer at the pharyngoesophageal junction.

Authors:  Peter Panhofer; Christopher Springer; Barbara Izay; Matthäus Grasl; Martin Burian; Sebastian F Schoppmann; Thomas Rath; Raimund Jakesz; Johannes Zacherl
Journal:  Langenbecks Arch Surg       Date:  2012-09-02       Impact factor: 3.445

5.  HDR brachytherapy (HDR-BT) combined with stent placement in palliative treatment of esophageal cancer.

Authors:  Marek Kanikowski; Janusz Skowronek; Magda Kubaszewska; Adam Chichel; Tomasz Piotrowski
Journal:  J Contemp Brachytherapy       Date:  2009-03-23

6.  Usefulness of the Clavien-Dindo Classification in Understanding the Limitations and Indications of Larynx-preserving Esophageal Reconstruction.

Authors:  Hiroki Umezawa; Junichi Nakao; Takeshi Matsutani; Hiroaki Kuwahara; Marie Taga; Rei Ogawa
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-11-11

7.  Microvascular Reconstruction of Free Jejunal Graft in Larynx-preserving Esophagectomy for Cervical Esophageal Carcinoma.

Authors:  Ayato Hayashi; Yuhei Natori; Masakazu Komoto; Takashi Matsumura; Masatoshi Horiguchi; Hidekazu Yoshizawa; Yoshimi Iwanuma; Masahioko Tsurumaru; Yoshiaki Kajiyama; Hiroshi Mizuno
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-03-03

8.  Long-term outcome of definitive radiotherapy for cervical esophageal squamous cell carcinoma.

Authors:  Katsuyuki Sakanaka; Yuichi Ishida; Kota Fujii; Satoshi Itasaka; Shin'ichi Miyamoto; Takahiro Horimatsu; Manabu Muto; Takashi Mizowaki
Journal:  Radiat Oncol       Date:  2018-01-18       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.